Kanzius in the News

Erie, Pa (September 18, 2012) – Kanzius Cancer Research Foundation (KCRF) announces Scott Burton as the closing guest speaker along with an updated agenda for their faces2012 conference.

The Kanzius Foundation announces their first national conference, faces2012, is now a two-day event. The conference will start Friday, October 26^th at 6:00 p.m. with an opening night welcome reception, “Meet the Researchers” and end Saturday, October 27^th at 4:45 p.m. with the closing session, “Don’t Stop Believing.”  

Breakout sessions highlighting investigators researching the Kanzius Noninvasive Radiowave Cancer Treatment, awareness techniques, and fundraising success stories will still take place throughout the day Saturday.

The agenda changes came about to accommodate the travel schedule of award-winning comedian, world-class juggler and cancer survivor, Scott Burton.  The 20-year survivor of osteosarcoma will be featured during the closing “Don’t Stop Believing,” session on Saturday (10/27) from 3:30-4:30 p.m. Burton will end faces2012 with his inspiring and entertaining message “Looking for Laughter in All the Wrong Places!”

“Scott Burton was selected as the closing speaker of faces2012 to reinforce the reason we are all gathering together in the first place. faces2012 is about the “people” behind the Kanzius Foundation: cancer patients, survivors, loved ones, researchers, medical professionals, donors and media – all uniting for “a better way” to treat the disease.  It is, however, also about living life to the fullest in the midst of it,” stated Mark A. Neidig, Sr., KCRF’s Executive Director. “Scott’s presentation will surely ignite the energy and passion that is needed to move our mission forward. He uses a unique blend of laughter and dexterity to motivate his audience; the perfect finale to the conference.”

Along with Burton, other keynote speakers include lead Kanzius researchers Dr. Steven Curley of The University of Texas MD Anderson Cancer Center (Houston), Dr. Hong Koo Kim of the University of Pittsburgh Medical Center, and Dr. Dustin Kruse of the University of California-Davis. All three will first be introduced during the opening night welcome reception, “Meet the Researchers.” Also, nationally syndicated television/radio host, media personality, author, entrepreneur, and very generous Kanzius Foundation supporter and advocate, Glenn Beck will share the dream of John Kanzius, his community and the responsibility to keep his dream alive during the noontime luncheon “Keeping an American Dream Alive” on Saturday, October 27^th.

The cost to attend the entire faces2012 two-day conference is $175.  For those wishing to only attend the Saturday activities, a fee of $125 will cover all sessions including meals and workshops.  Single tickets are available to meet the Kanzius researchers on Friday evening ($50) and the “Keeping an American Dream Alive” luncheon ($100).  Please visit www.faces2012.org for links to register as well as a complete agenda and additional conference information.

To view video clips of Glenn Beck’s 12/7/11 broadcast on John Kanzius’ big dream, visit http://www.kanziuscancerresearch.org/news-and-updates/media-library/a-cure-for-cancer-perhaps-glenn-beck-on-kanzius and a sneak preview of Scott Burton visit http://www.kanziuscancerresearch.org/news-and-updates/media-library. 

####

Click here for Scott Burton video.

Click here for press conference video.

About the Kanzius Cancer Research Foundation

The Kanzius Cancer Research Foundation is a 501(c)(3) nonprofit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses through human trials. The goal of KCRF is to raise money to support ongoing research grants. Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic, osteosarcomic and prostate cancers.  For more information about the Kanzius research, visit www.Kanzius.org.